Activation Capital

Light Switch Bio reduces the adverse effects and healthcare burdens of systemic toxicities and repurposes existing drugs for pharmaceutical companies as a pre-clinical service to benefit their patients and market reach, and co-develop software to de-risk R&D and optimize clinical dosimetry and response predictability.

PEEL Therapeutics, Inc. is a clinical-stage biotechnology company based in Salt Lake City, Utah, that focuses on developing cancer-fighting therapeutics derived from proteins found in elephants. Incorporated in 2015, the company utilizes its proprietary platform to create anti-cancer protein nanoparticles, specifically elephant p53 (EP53), which are designed to regulate cellular responses to environmental stresses. This approach aims to stimulate gene transcription related to cell cycle arrest, apoptosis, and metabolism, thereby enhancing the treatment and potential cure for cancer and inflammatory diseases. In addition to its primary focus on cancer therapeutics, PEEL Therapeutics is exploring new drug candidates that leverage natural biological mechanisms to address various health challenges.

KeViRx is a biotechnology company focused on developing therapeutics for cancer and respiratory disorders. The company specializes in drug discovery, aiming to advance new small molecule therapeutics to clinical testing. Its lead product is an allosteric protein tyrosine phosphatase small molecule inhibitor that has demonstrated efficacy in in-vivo models for various conditions, including ovarian cancer, acute myeloid leukemia, and acute lung injury. By focusing on these areas, KeViRx seeks to address significant unmet medical needs in the healthcare sector.

Vizma Life Sciences develops next-generation molecular imaging and chemical analysis solutions.

Rapid Forensic Cell Typing helps forensic investigators to identify which evidence samples contain useful biological information.

GenAssist began commercializing biomimetic sponges to treat muscle loss in human patients after observing a notable recovery in muscular function after a composite trauma model of muscle loss.

Oncoustics is focused on enhancing clinical workflow productivity through the development and deployment of advanced artificial intelligence solutions for non-invasive disease monitoring. The company utilizes AI to analyze raw ultrasound signals from accessible handheld devices, enabling rapid differentiation between healthy and diseased tissues. This innovative approach uncovers novel acoustic biomarkers that align with established medical standards. Initially concentrating on liver disease, which represents a significant global diagnostic market, Oncoustics has pursued Breakthrough Device Designation from the FDA for its OnX device, designed to detect liver fibrosis, and is progressing with a 510K filing. The company is also advancing several additional liver-related products and has gathered clinical data on various other organ conditions, including prostate, kidney, breast, and thyroid diseases and cancers.

Gisens Biotech is a biotechnology firm specializing in bioelectronics and nanotechnology. The company is recognized for its innovative approach to problem-solving and employs advanced technology to enhance its offerings. One of its flagship products is the Nano-Lab, a portable diagnostic device designed to measure and control various biomarkers. This device can accurately analyze concentrations of renal biomarkers such as urea, creatinine, and potassium from a single drop of blood, urine, or saliva. By providing real-time measurements through a user-friendly application, the Nano-Lab enables efficient health monitoring, potentially transforming the way biomarker assessments are conducted and interpreted.

OrthoPreserve is a clinical technology business. It provides artificially created meniscus replacement implants.

Atticus Pharma developed a unique, sustained-release system for delivering therapeutics directly to the skin represents an exciting advancement in drug delivery technology.

Lighthouse Labs RVA helps entrepreneurs grow their startups by providing resources and support to validate business models and attract customers. Their accelerator lab program has successfully worked with 33 companies in the past 5 years, helping them raise over $25 million in financing. With a focus on real customer validation and a strong team of founders, Lighthouse Labs RVA assists startups in reaching their full potential. Whether you are looking to raise capital, bootstrap your idea, or crowdfund your business, they offer pre-acceleration resources to help you prepare for success.